179 related articles for article (PubMed ID: 21095449)
1. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Geissler EK
Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
[TBL] [Abstract][Full Text] [Related]
2. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
4. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
Paoletti E; Cannella G
Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
6. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
7. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
Sola E; Lopez V; Gutierrez C; Cabello M; Burgos D; Molina MG; Hernandez D
Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
[TBL] [Abstract][Full Text] [Related]
8. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
9. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
Gaumann A; Schlitt HJ; Geissler EK
Transpl Int; 2008 Mar; 21(3):207-17. PubMed ID: 18069922
[TBL] [Abstract][Full Text] [Related]
11. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
12. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
[TBL] [Abstract][Full Text] [Related]
13. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
14. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
15. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin.
Paoletti E; Cannella G
Transplant Proc; 2009; 41(6 Suppl):S3-5. PubMed ID: 19651293
[TBL] [Abstract][Full Text] [Related]
16. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
17. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
19. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
[TBL] [Abstract][Full Text] [Related]
20. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
